UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016380
Receipt number R000018910
Scientific Title Nationwide registry for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan
Date of disclosure of the study information 2015/01/31
Last modified on 2021/02/04 15:43:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Nationwide registry for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan

Acronym

Nationwide NET registry

Scientific Title

Nationwide registry for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan

Scientific Title:Acronym

Nationwide NET registry

Region

Japan


Condition

Condition

Pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine Pneumology
Endocrinology and Metabolism Gastrointestinal surgery Hepato-biliary-pancreatic surgery
Chest surgery Endocrine surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To establish nationwide registry and database for clinical study/clinical trial for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan and to clarify the characteristics of those patients

Basic objectives2

Others

Basic objectives -Others

Neuroendocrine Tumor

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Prognosis of the disease

Key secondary outcomes

Not Applicable


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patient with pathological diagnosis as defined below after Jan 1st 2012 who are receiving follow-up examination after institutional IRB/IEC approval
a) NET G1/G2, NEC, or MANEC as pancreatic or gastroenteral neuroendocrine tumors
b) TC (Typical carcinoid), AC (Atypical carcinoid), LCNEC (Large cell neuroendocrine carcinoma) as bronchopulmonary neuroendocrine tumors
c) Any type of thymic neuroendocrine tumors

2) Patient with pancreatic, gastroenteral, bronchopulmonary, and thymic NET
3) Written informed consent (written informed consent from their parents or their legal representative who may represent their intent and interest will be needed when subjects are under 20 years old)

Key exclusion criteria

1) Patient with pathologically diagnosed small cell lung cancer (SCLC) as bronchopulmonary neuroendocrine tumors
2) Patients previously enrolled into this study
3) Patients regarded as ineligible for other reason by the investigator.

Target sample size

1800


Research contact person

Name of lead principal investigator

1st name Shinji
Middle name
Last name Uemoto

Organization

Kyoto University Hospital

Division name

Department of Surgery

Zip code

606-8507

Address

54 Shogoin Kawaharacho Sakyoku Kyoto

TEL

075-751-3242

Email

jnets-office@umin.ac.jp


Public contact

Name of contact person

1st name Toshihiko
Middle name
Last name Masui

Organization

Japan Neuroendocrine Tumor Society

Division name

Secretariat

Zip code

606-8507

Address

Kyoto Univerity, Department of Surgery, 54 Shogoin Kawaharacho Sakyoku Kyoto

TEL

075-751-3242

Homepage URL

http://jnets.umin.jp/index.html

Email

jnets-office@umin.ac.jp


Sponsor or person

Institute

Japan Neuroendocrine Tumor Society

Institute

Department

Personal name



Funding Source

Organization

Japan Neuroendocrine Tumor Society

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Translational Research Center for Medical Innovation

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Graduate School and Faculty of Medicine, Ethics Committee

Address

Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, JAPAN

Tel

075-753-4642

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

TRINET1332

Org. issuing International ID_1

Translational Research Center for Medical Innovation

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

膵・消化管: 330施設
肺・気管支・胸腺: 25施設


Other administrative information

Date of disclosure of the study information

2015 Year 01 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 12 Month 26 Day

Date of IRB

2015 Year 01 Month 14 Day

Anticipated trial start date

2015 Year 01 Month 23 Day

Last follow-up date

2024 Year 11 Month 30 Day

Date of closure to data entry

2024 Year 11 Month 30 Day

Date trial data considered complete

2024 Year 11 Month 30 Day

Date analysis concluded

2024 Year 11 Month 30 Day


Other

Other related information

The registration consists of basic questions. As this study is an exhaustive survey, we do not limit the schedule of observation or the treatment option.


Management information

Registered date

2015 Year 01 Month 29 Day

Last modified on

2021 Year 02 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018910


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name